MARKET

PRPO

PRPO

PRECIPIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.840
-0.660
-14.67%
After Hours: 3.660 -0.18 -4.69% 19:59 05/07 EDT
OPEN
4.290
PREV CLOSE
4.500
HIGH
4.600
LOW
3.640
VOLUME
9.49M
TURNOVER
--
52 WEEK HIGH
9.18
52 WEEK LOW
0.6500
MARKET CAP
69.63M
P/E (TTM)
-2.9698
1D
5D
1M
3M
1Y
5Y
Global Molecular Cytogenetics Market Analysis, Strategic planning, 2021 Top key Market Researcher, Price, Gross Margin, Business, Trend, Forecast 2023
May 07, 2021 (The Expresswire) -- Global "Global Molecular CytogeneticsMarket" (2021-2023) report identifies Sales of Market by regional analysis by product...
The Express Wire · 1d ago
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume.
Benzinga · 2d ago
58 Stocks Moving In Thursday's Mid-Day Session
Gainers
Benzinga · 2d ago
Thinking about buying stock in Nemaura Medical, Ocugen, Ambev, Precipio, or Vaxart?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NMRD, OCGN, ABEV, PRPO, and VXRT.
PR Newswire - PRF · 2d ago
30 Stocks Moving in Thursday's Pre-Market Session
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares rose 94.2% to $2.33 in pre-market trading. Stealth BioTherapeutics showcased data for Elamipretide in dry age-related macular degeneration at the 2021 ARVO Annual Meeting.
Benzinga · 3d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Benzinga · 3d ago
ADMP, BGFV, ATNX and ESPR among midday movers
Gainers: Regional Health Properties (RHE) +124%.SunLink Health Systems (SSY) +66%.Nemaura Medical (NMRD) +60%.Chiasma (CHMA) +48%.Athenex (ATNX) +31%.Caesarstone (CSTE) +30%.Hayward (HAYW) +28%.Altisource Portfolio Solutions (ASPS) +26%.Big 5 Sporting Good...
Seekingalpha · 3d ago
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares jumped 64.9% to $7.75 after the company reported an order for 200,000 sugarBEAT sensors.
Benzinga · 3d ago
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRPO. Analyze the recent business situations of PRECIPIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRPO stock price target is 6.65 with a high estimate of 7.00 and a low estimate of 6.30.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 866.42K
% Owned: 4.78%
Shares Outstanding: 18.13M
TypeInstitutionsShares
Increased
6
167.00K
New
7
187.41K
Decreased
0
0
Sold Out
6
120.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.95%
Healthcare Equipment & Supplies
+0.66%
Key Executives
Chairman/Director
Richard Sandberg
President/Chief Executive Officer/Director
Ilan Danieli
Chief Financial Officer
Carl Iberger
Vice President/Director of Sales
Douglas Sites
Chief Operating Officer
Ahmed Sabet
Other
Ori Karev
Other
Stephen Miller
Director
Ronald Andrews
Director
David Cohen
Director
Douglas Fisher
Independent Director
Jeffrey Cossman
Independent Director
Kathleen LaPorte
No Data
  • All
  • Financials
  • Insiders
More
About PRPO
Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.

Webull offers kinds of Precipio Inc stock information, including NASDAQ:PRPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRPO stock methods without spending real money on the virtual paper trading platform.